The total return over the past 12 months is +53.09% vs. +16.94% for the S&P 500. So far it's up +20.59% this year. Includes price appreciation + reinvested dividends.
| Category | 1Y (TTM) | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Price CAGR | +53.09% | +3.83% | (23.16%) | N/A | N/A | N/A |
| Total Return CAGR | +53.09% | +3.83% | (23.16%) | N/A | N/A | N/A |
| Revenue CAGR | +5.44% | +5.59% | +13.37% | N/A | N/A | N/A |
| Net Income CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| EPS CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow CAGR | (209.18%) | N/A | N/A | N/A | N/A | N/A |
| Operating Cash Flow CAGR | (139.72%) | N/A | N/A | N/A | N/A | N/A |
| Dividends CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
Visualize historical growth rates over rolling horizons. Use the dropdown to select different metric vectors.
Cytek Biosciences, Inc. (CTKB)
| Year | Start price | End price | CTKB Return | SPY Return | Outperformance |
|---|---|---|---|---|---|
| 2026(YTD) | $5.05 | $6.09 | +20.59% | +14.51% | +6.08% |
| 2025 | $6.49 | $5.05 | (22.19%) | +17.72% | (39.91%) |
| 2024 | $9.12 | $6.49 | (28.84%) | +24.89% | (53.73%) |
| 2023 | $10.21 | $9.12 | (10.68%) | +26.19% | (36.87%) |
| 2022 | $16.32 | $10.21 | (37.44%) | (18.17%) | (19.27%) |
Start and end prices are split-adjusted closing prices. Total return includes reinvested dividends, so it can differ from the price change.
